Acquired Deficit of Antithrombin and Role of Supplementation in Septic Patients During Continuous Veno-Venous Hemofiltration
Authors:
- 1 January 2008
- journal article
- research article
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 54 (1) , 124-128
Abstract
Continuous renal replacement therapy (CRRT) is widely used in the management of septic patients with acute renal failure (ARF). Short filter lifespan (p < 0.05). Continuous infusion provided better results: 48.5 vs. 27.8 hours for bolus method. This study suggests that AT measurement should be considered in continuous veno-venous hemofiltration with clotting problems as supplementation could increase filter lifespan by more than 100%. Continuous infusion is preferable. Cost effectiveness should be evaluated shortly.Keywords
This publication has 33 references indexed in Scilit:
- Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patientsKidney International, 2005
- Acute Renal Failure and SepsisNew England Journal of Medicine, 2004
- Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients*Critical Care Medicine, 2002
- Different patterns of heparin resistance: therapeutic implicationsPerfusion, 2002
- Clinical trial results with antithrombin III in sepsisCritical Care Medicine, 2000
- Antithrombin III During Cardiac SurgeryAnesthesia & Analgesia, 1997
- Pathogenetic Mechanisms of Septic ShockNew England Journal of Medicine, 1993
- Sepsis, the Sepsis Syndrome, Multi-Organ Failure: A Plea for Comparable DefinitionsAnnals of Internal Medicine, 1991
- Antithrombin-III and Platelets in Haemodialysis PatientsNephron, 1981
- HEPARIN-INDUCED DECREASE IN CIRCULATING ANTITHROMBIN-IIIThe Lancet, 1977